Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 9/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | STK25 | O00506 | 1/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.37 |
| ▸ | CDK2 | P24941 | 2/20 | 0.37 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | MMP2 | P08253 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13388276 | 0.93 | MAPK1 (0.38) | MAPK1HPGDJAK2JAK1JAK3 | |
| SCHEMBL13387617 | 0.84 | MAPK1 (0.36) | MAPK1HPGDCCNA2CDK2CCNA1 | |
| Trifluoroacetic Acid SCHEMBL13387652 | 0.82 | CPB2 (0.40) | MAPK1CA12CA1CA2CA9 | |
| SCHEMBL13256448 | 0.77 | CCNA2 (0.53) | HPGDCCNA2CDK2CCNA1 | |
| SCHEMBL13387620 | 0.76 | SMN1; SMN2 (0.44) | CCNA2CDK2CCNA1CA12 | |
| SCHEMBL19101944 | 0.72 | DYRK1A (0.38) | CCNA2CDK2CCNA1 | |
| SCHEMBL3932634 | 0.71 | MAPK8 (0.55) | HPGDPOLB | |
| SCHEMBL13387759 | 0.70 | NQO2 (0.37) | — | |
| SCHEMBL1906671 | 0.70 | HDAC3 (0.38) | MAPK1HPGDCA1CA2 | |
| SCHEMBL1908029 | 0.68 | ALDH1A1 (0.38) | CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481494-B2 | Compounds for the treatment of diseases related to protein misfolding | UNIVERSITAT DUISBURG-ESSEN (DE) | 2013-07-09 | — | — | US | disclosed |
| US-20120270795-A1 | COMPOUNDS FOR THE TREATMENT OF DISEASES RELATED TO PROTEIN MISFOLDING | UNIVERSITAT DUISBURG-ESSEN (DE) | 2012-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270795-A1 | COMPOUNDS FOR THE TREATMENT OF DISEASES RELATED TO PROTEIN MISFOLDING | APP, PRNP, PSEN1 | MAPK1 1482/4885HPGD 1496/4885JAK2 4183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.